Lupin receives US FDA Establishment Inspection Report for Somerset facility

Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset, New Jersey. The report follows an inspection conducted from 27 January to 31 January 2025.

Nilesh Gupta, Managing Director of Lupin, stated, “We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a leading pharmaceutical manufacturer.”

Related Posts

  • Pharma
  • April 2, 2025
  • 68 views
11 substandard drugs in use in Telangana, finds Central Drugs Standard Control Organisation

HYDERABAD:  At least 11 generic drugs, including painkillers, antibiotics, and cough syrups in use in Telangana were found to be ‘not of standard quality’ (NSQ) by the Union health ministry’s…

  • Pharma
  • April 2, 2025
  • 68 views
Piramal Pharma’s Telangana unit starts production of general anesthesia drug Sevoflurane

Piramal Pharma said that it has commenced the commercial production of Sevoflurane at the company’s facility located at Digwal, Telangana, India. This was achieved by creating capacity for Sevoflurane manufacture…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

11 substandard drugs in use in Telangana, finds Central Drugs Standard Control Organisation

11 substandard drugs in use in Telangana, finds Central Drugs Standard Control Organisation

Piramal Pharma’s Telangana unit starts production of general anesthesia drug Sevoflurane

Piramal Pharma’s Telangana unit starts production of general anesthesia drug Sevoflurane

3 lotion companies fail to prove ‘skin whitening’ claims, fined

3 lotion companies fail to prove ‘skin whitening’ claims, fined

Alembic Pharma receives USFDA final approval for Pantoprazole Sodium Injection

Alembic Pharma receives USFDA final approval for Pantoprazole Sodium Injection